Please see the below, and attached, information from our partners in the Federal Emergency Management Agency (FEMA) regarding an update on the Whole-of-America response to COVID-19.

May 19, 2020

FEMA Advisory

Coronavirus (COVID-19) Pandemic: Whole-of-America Response

Attached you will find today’s FEMA Daily Briefing Points for the Whole-of-America response to the coronavirus (COVID-19) pandemic. These briefing points include Topline Messages, as well as information By the Numbers; Supply Chain Task Force; FEMA and Department of Health and Human Services Response; and Guidance from Federal Agencies.

Topline messaging includes:

- On May 18, HHS announced $11 billion in funding to states, territories and tribes to support testing for COVID-19. This funding is part of the Administration’s efforts to ensure that states, territories, and tribes have the resources necessary to meet their testing goals as they begin to reopen.
  - The CDC will provide $10.2 billion to states, territories, and local jurisdictions through CDC’s existing Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases cooperative agreement.
  - The Indian Health Service will provide $750 million to IHS, tribal, and urban Indian Health programs to expand testing capacity and testing-related activities.
  - This funding from the Paycheck Protection Program and Health Care Enhancement Act will provide critical support to develop, purchase, administer,
process and analyze COVID-19 tests, conduct surveillance, trace contacts and related activities.

- As of May 18, FEMA, HHS, and the private sector combined have coordinated the delivery of or are currently shipping: 82.7 million N95 respirators, 133.7 million surgical masks, 11.6 million face shields, 24.4 million surgical gowns, and 989.4 million gloves.
- FEMA has procured and delivered 5.2 million swabs and 3 million units of media so far in the month of May. In support of the White House Task Force’s testing initiative, FEMA is supporting the procurement of specimen collection supplies to supplement the supplies states and healthcare providers are procuring from the private market.
- As of May 18, CDC, state, and local public health labs and other laboratories have tested more than 10.8 million samples.
  - As of May 18, the FDA has issued 103 individual emergency use authorizations (EAU) for test kit manufacturers and laboratories, including 12 antibody tests and 1 antigen test.
- On May 15, President Trump announced Operation Warp Speed. The goal of this national program is to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.
  - Operation Warp Speed is a public-private partnership between components of HHS, the Department of Defense, private firms and other federal agencies.
  - The program aims to have substantial quantities of a safe and effective vaccine available for Americans by January 2021.

Follow Us

Follow FEMA on social media at: Visit the FEMA Blog, follow @FEMA or @FEMAEspanol on Twitter, FEMA or FEMA Espanol on Facebook, @FEMA on Instagram, and view videos on the FEMA YouTube channel, and Administrator Pete Gaynor on Twitter @FEMA_Pete.

FEMA Mission

To help people before, during, and after disasters.

# # #

- ESF15_DailyBriefingPoints_20200519_FINAL.pdf
- COVID-19 By the Numbers 5.19.20.pdf

Having trouble viewing this message? View it as a webpage.

You are subscribed to updates from the U.S. Department of Homeland Security
Manage Subscriptions | Privacy Policy | Help

If you were forwarded this email and would like to be added to future DHS Intergovernmental Affairs distributions, please register your email address here.
Mercury.

Rob Smith
Managing Director
300 Tingey Street SE | Suite 202
Washington, DC | 20003
202.261.4000 office | 202.258.5486 mobile
www.mercuryllc.com

This email may contain material that is subject to copyright or trade secret protection, confidential and/or privileged and, in all cases, provided for the sole use of the intended recipient. Any review, reliance or distribution by others or forwarding without express permission is strictly prohibited. If you are not the intended recipient, please contact the sender and delete all copies. Omnicom Group Inc. and its affiliates (“Omnicom”) may monitor the use of this email system for various purposes including security management, system operations, and intellectual property compliance. Omnicom’s email systems may not be used for the delivery of unsolicited bulk email communications.